Tesamorelin vs Sermorelin: Approved Label vs Compounded Habit

The short answer: tesamorelin and sermorelin do the same basic job. Both are copies of growth-hormone-releasing hormone (GHRH) that tell the pituitary to release more of its own growth hormone. The difference is the evidence behind them. Tesamorelin has a current FDA label, as Egrifta, and large randomized trials showing it cuts deep belly fat and liver fat in people with HIV¹²³. Sermorelin's approval, as Geref, was for children with growth hormone deficiency, the product was discontinued in 2008, and the adult trials behind today's prescriptions are small and short⁴⁵⁷.

The surprise for buyers runs the other way from the marketing. Sermorelin is the one sold as an anti-aging and body-composition peptide, but tesamorelin is the one with trial results on fat. And at the same clinic, the two often cost nearly the same.

Same Signal, Different Molecules

Natural GHRH is a 44-amino-acid hormone. The two drugs are built from it in different ways.

Sermorelin is a 29-amino-acid analog of GHRH, matching the first 29 amino acids of the natural hormone¹⁰. It is the same signal, trimmed down.

Tesamorelin is the full 44-amino-acid sequence with a small chemical group, a six-carbon hexenoyl chain, attached to the front of the molecule¹. Its label gives an elimination half-life of about 11 minutes after an under-the-skin injection¹.

Both act on the same receptor in the pituitary, and in both cases the drug itself disappears quickly while the growth hormone and IGF-1 it triggers last longer. That is why neither is dosed by how long the molecule lingers. Both are daily injections in their studied forms.

What Each Was Tested For

This is where they split.

Tesamorelin was tested for one specific problem: fat that builds up around the organs in people with HIV on antiretroviral therapy. In the first phase 3 trial, 412 patients injected 2 mg daily or placebo for 26 weeks. Deep abdominal (visceral) fat fell 15.2% on tesamorelin and rose 5.0% on placebo, triglycerides fell, and IGF-1 rose 81%². A pooled analysis of two phase 3 trials with 806 patients confirmed the effect and found it held to 52 weeks in people who stayed on the drug, with no clinically meaningful change in glucose measures⁶. The label is for exactly that use, reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and says outright that tesamorelin is not indicated for weight loss because its effect on weight is neutral¹.

Sermorelin was tested in children. In its main treatment study, 110 children with growth hormone deficiency took a bedtime injection for up to a year, and their growth rate roughly doubled in the first six months⁵. The adult studies are small. Ten older men on twice-daily injections for two weeks saw growth hormone and IGF-1 rise to young-adult levels⁸. Eleven older men on nightly injections for six weeks saw no change in weight, muscle or fat on body scans⁷. Nineteen older adults on a closely related analog for four months saw lean mass rise in men only and no other change in body composition⁹.

So when a clinic sells either one for body composition in healthy adults, neither has been tested for that. Tesamorelin at least has fat-loss trials in a real patient group. Sermorelin does not.

How Each Is Dosed

Tesamorelin has a labeled dose, and it depends on the product. The current Egrifta WR label is 1.28 mg injected under the skin of the abdomen once daily; one vial is mixed with 1.3 mL of the supplied bacteriostatic water and covers seven days¹. The trials that earned the approval used 2 mg daily of the original formulation²³. The label warns that its formulations are not interchangeable, which is a good reason to be wary of anyone converting a branded dose into a different vial.

Sermorelin has no current labeled dose for adults. The pediatric product was given at 30 micrograms per kilogram at bedtime⁵. The adult studies used 0.5 mg or 1 mg twice daily for two weeks⁸ and 2 mg nightly for six weeks⁷. The protocols sold today come from clinic practice rather than from those trials, a point covered in sermorelin dosage.

Liver Fat: The Tesamorelin Finding Rarely Mentioned

The most interesting tesamorelin result is not the belly fat. In a randomized, double-blind trial of 61 people with HIV and fatty liver disease, a year of 2 mg daily cut liver fat by an absolute 4.1 percentage points against placebo, a 37% relative drop from baseline. 35% of the tesamorelin group got their liver fat under the 5% threshold, against 4% on placebo, with no difference in fasting glucose or HbA1c at 12 months³. The tesamorelin group had more injection-site complaints, none serious³.

It is still one modest trial in one patient group. But it is a hard clinical endpoint, and there is nothing like it for sermorelin.

Side Effects Side by Side

Both share the risks of raising growth hormone: fluid retention, joint pain and blood-sugar effects. Tesamorelin's are counted on a label; sermorelin's mostly are not.

On the tesamorelin label, injection-site reactions affected 25% of patients against 14% on placebo in the first 26 weeks, and 5% developed an HbA1c of 6.5% or higher against 1% on placebo¹. The label warns about fluid retention, glucose intolerance, hypersensitivity, and elevated IGF-1, and it is contraindicated in active cancer and pregnancy¹.

For sermorelin, the pediatric program recorded transient facial flushing and injection-site pain as the most common events¹⁰, and the short adult studies reported few problems⁷⁸. That is a smaller record, not necessarily a safer drug. Both are covered in detail in tesamorelin side effects and sermorelin side effects.

What a Prescriber Should Check With Either

Because both drugs work by raising growth hormone, the sensible checks are the same, and the tesamorelin label spells them out¹:

• •IGF-1 before starting and during treatment. The label suggests considering a stop if IGF-1 stays well above normal, especially if the drug is not clearly working.
• •Blood sugar, before and periodically. On tesamorelin, HbA1c of 6.5% or higher was five times as common as on placebo.
• •Eye checks in people with diabetes, because higher IGF-1 can worsen diabetic retinopathy.
• •Cancer history. Any past cancer should be inactive and fully treated first, and the drug stopped if it returns.

None of this is required for sermorelin, because it has no label. That is exactly why it is worth asking for.

Price Per Month

The cleanest way to compare price is to look at clinics that sell both, because then the only thing that changes is the molecule. Figures below are from each company's own public pages, as recorded in our reviews in August and September 2026.

• •Vyora Wellness lists sermorelin at $189 and tesamorelin at $279 a month, though it ships every three weeks.
• •ElitePhysiqMD's subscribe-and-save menu has sermorelin at $267.30 and tesamorelin at $274.50, well above its homepage entry price.
• •NEUVÉ Health's single price table puts sermorelin at $184 and tesamorelin at $225, as program figures rather than all-in prices.
• •Rehydra+ starts sermorelin from $250 and tesamorelin from $399, on six-month non-cancelable plans.
• •Live Vital lists tesamorelin at $166 a month, on a protocol whose length decides what a month really costs.

Across the sermorelin market as a whole, the typical month-to-month price sits around $185; the full spread is in sermorelin cost, and providers are compared on the sermorelin board. Tesamorelin usually costs more at the same seller, by anywhere from a few dollars to about $150 a month.

Labels, Compounding and Sport

Tesamorelin is FDA-approved today as Egrifta, but only for HIV-associated abdominal fat¹. A clinic offering it for anything else is prescribing off-label. Ask whether you are getting the branded product or a compounded version, because only the brand carries the label's testing behind it.

Sermorelin has no marketed approved product. Geref was discontinued in 2008, and FDA formally determined in 2013 that it was not withdrawn for reasons of safety or effectiveness⁴. Every sermorelin vial sold today is compounded, and compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness or quality before sale¹¹.

In sport, both are named on the World Anti-Doping Agency's 2026 Prohibited List under growth hormone releasing factors, prohibited at all times¹². For athletes the comparison ends there; see tesamorelin and athletes.

Which Question Each One Answers

Tesamorelin answers a specific medical question: in an adult with HIV and excess visceral or liver fat, will this reduce it? The trials say yes, while you keep taking it. Dosing for the labeled products is covered in tesamorelin dosage, and the tesamorelin dosage calculator converts a dose into syringe units.

Sermorelin answers a narrower, older question: can a GHRH signal restore growth hormone in someone whose pituitary responds? In children with deficiency, yes. In healthy older adults, it raises growth hormone and IGF-1, and the body-composition payoff in the small trials was slight. If you are deciding between sermorelin and a different secretagogue instead, see sermorelin vs ipamorelin.

Bottom Line

Same signal, very different paperwork. Tesamorelin is the better-studied molecule, with a current label, randomized trials on visceral and liver fat, and counted side effects, but its evidence is in HIV-associated fat, not healthy adults. Sermorelin is the cheaper, more widely sold habit, with a pediatric approval history and small adult studies that raised hormone levels more than they changed bodies. Neither is a weight-loss drug, both are banned in tested sport, and either one should come with IGF-1 and glucose checks. This page is educational, not medical advice.